Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL

Abstract

<jats:title>Key Points</jats:title> <jats:p>Higher ibrutinib DI is associated with improved PFS, independent of del17p or TP53 mutation. Ibrutinib hold for &gt;1 week, often needed to manage adverse events, is associated with increased PFS events.</jats:p>